30 mar: Aktieetilbagekøbsprogram i SP Group A/S
30 mar: Børsmeddelelse nr. 20.2017 Indkaldelse til ordinær generalforsaml..
30.03.2017 13:09:12

Lundbeck held its Annual General Meeting on 30 March 2017 at the company’s registered office

Relateret indhold
17:04 - 
Mandagens aktier: Novo og TDC snuppede podiepladserne i..
11:42 - 
Aktier/middag: Lundbeck og TDC topper positivt marked
17 maj - 
Aktier/middag: NKT lyser op i rødt marked - IC og Vestj..
Relateret debat
10 maj - 
Godt regnskab. Er det nu, man skal ind i aktien ?.
09 maj - 
I morgen kl ca 8,00 er der nyt om regnskab. Jyske og No..
03 maj - 
jeg venter også til den kommer lige under 300 jeg..

Valby, Denmark, 2017-03-30 13:09 CEST (GLOBE NEWSWIRE) --

Valby, Denmark, 30 March 2017 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

The proposal to distribute a dividend of 40% of the net profit for the accounting year 2016, corresponding to DKK 2.45 per share, or a total dividend of DKK 484 million, was adopted.

Lars Rasmussen, Lene Skole, Lars Holmqvist and Jesper Ovesen were re-elected to the Board of Directors. In addition, Jeremy M. Levin was elected to the Board of Directors. Terrie Curran did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Rasmussen as Chairman and Lene Skole as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

  • Lars Rasmussen (Chairman)

  • Lene Skole (Deputy Chairman)

  • Lars Holmqvist

  • Jesper Ovesen

  • Jeremy M. Levin

  • Mona Elisabeth Elster (employee representative)

  • Jørn Møller Mayntzhusen (employee representative)

  • Henrik Sindal Jensen (employee representative)

 

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the Audit Committee. Lars Rasmussen and Lene Skole were elected as members of the Remuneration Committee. Jeremy M. Levin and Lene Skole were elected as members of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for the year 2017.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal to give the Board of Directors authorization to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted.

The Chairman of the General Meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the Annual General Meeting.

The Board of Directors

 

Lundbeck contacts

Investors:

Media:

 

 

Palle Holm Olesen

Mads Kronborg

Vice President,  Investor Relations

Senior Director, Corp. Communication

palo@lundbeck.com

mavk@lundbeck.com

+45 30 83 24 26

+45 36 43 40 00

 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

 

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Vedhæftet fil: UK_PDF.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Vestas/Jyske: Tysk prispres er håndterbart

22-05-2017 15:06:16
Det nye auktionsbaserede system for opførelse af landbaserede vindparker i Tyskland viser tegn på prispres, men dog ikke i et omfang som frygtet.Det skriver aktieanalytiker Janne Vincent Kjær fra Jyske Bank, som mener, at det er håndterbart for Vestas.- Selv om der er et pres fra kunderne for at reducere prisen på vindenergi, og priserne per megawatt-time er faldende, ser vi ikke noget markant pri..

GE's køb af dansk vingeproducent skal under EU-lup - citat

22-05-2017 14:42:21
Amerikanske General Electrics (GE) overtagelse af den danske vingeprocent LM Wind Power skal undersøges af EU-Kommissionen, skriver Bloomberg News med henvisning til to kilder med indblik i sagen.Kommissionen skal efter sigende vurdere, om GE vildledte de EU's embedsmænd, der undersøgte aftalen med LM Wind Power. GE skulle ifølge en af kilderne have fortalt, at selskabet ikke har planer om at udvi..

Aktier/åbning: Olieprisen løfter Mærsk

22-05-2017 09:21:56
Prisstigninger på olie har mandag morgen løftet A.P. Møller-Mærsk fra åbningen, hvor stigningerne generelt i er overtal.C20 Cap-indekset stiger med 0,4 pct. til 1146,25 efter plusser i 16 af de 20 elitemedlemmer.Mærsks A-aktie ligger helt i toppen efter en stigning på 0,9 pct. til 11.810 kr. Mandag morgen er olieprisen i fokus. Prisen på en tønde nordsøolie, Brent, stiger 0,7 pct. til lige over 54..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske: Investorerne vil benytte enhver "undskyldning" til at sælge ud
2
Pandora: Kursfald skræmmer ikke analytikerne væk
3
Zealand/Jefferies: Soliqua spås milliardpotentiale i dollar
4
Vestas: Suzlon tager tigerspring efter regnskab
5
Aktier/tendens: Olieprisen kan løfte Mærsk

Relaterede aktiekurser

Lundbeck A/S 343,70 1,6% Stigning i aktiekurs
H.Lundbeck A/S DKK5 51,16 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. maj 2017 23:29:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB7 - 2017-05-22 23:29:09 - 2017-05-22 23:29:09 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x